Eckhardt, Tamira, Goddard, Richard, Lehmann, Christoph, Richter, Adrian, Sahile, Henok Asfaw, Liu, Rui, Tiwari, Rohit, Oliver, Allen G., Miller, Marvin J., Seidel, Rüdiger W., and Imming, Peter
1,3‐Benzothiazin‐4‐ones (BTZs) are a promising new class of drugs with activity against Mycobacterium tuberculosis, which have already reached clinical trials. A product obtained in low yield upon treatment of 8‐nitro‐2‐(piperidin‐1‐yl)‐6‐(trifluoromethyl)‐4H‐benzothiazin‐4‐one with 3‐chloroperbenzoic acid, in analogy to a literature report describing the formation of sulfoxide and sulfone derived from BTZ043 [Tiwari et al. (2015). ACS Med. Chem. Lett.6, 128–133], is a ring‐contracted benzisothiazolinone (BIT) 1‐oxide, namely, 7‐nitro‐2‐(piperidine‐1‐carbonyl)‐5‐(trifluoromethyl)benzo[d]isothiazol‐3(2H)‐one 1‐oxide, C14H12F3N3O5S, as revealed by X‐ray crystallography. Single‐crystal X‐ray analysis of the oxidation product originally assigned as BTZ043 sulfone provides clear evidence that the structure of the purported BTZ043 sulfone is likewise the corresponding BIT 1‐oxide, namely, 2‐[(S)‐2‐methyl‐1,4‐dioxa‐8‐azaspiro[4.5]decane‐8‐carbonyl]‐7‐nitro‐5‐(trifluoromethyl)benzo[d]isothiazol‐3(2H)‐one 1‐oxide, C17H16F3N3O7S. A possible mechanism for the ring contraction affording the BIT 1‐oxides instead of the anticipated constitutionally isomeric BTZ sulfones and antimycobacterial activities thereof are discussed. [ABSTRACT FROM AUTHOR]